Amol K. Narang, MD

• Vice Chair of Clinical Operations
• Medical Director, Johns Hopkins Hospital
• Co-Director of the Johns Hopkins Pancreatic Cancer Multi-Disciplinary Clinic

Associate Professor of Radiation Oncology and Molecular Radiation Sciences

• Sidney Kimmel Comprehensive Cancer Center
• Skip Viragh Center for Pancreatic Cancer

https://www.linkedin.com/in/amol-narang-21107789

Pancreatic Cancer, Stereotactic Body Radiation Therapy, Baltimore Triangle, IntraOperative Radiation

Associate Professor of Oncology, Associate Professor of Surgery

Pancreatic Cancer, radiation therapy, stereotactic body radiation therapy, intraoperative radiation therapy

Dr. Narang’s primary research interest is development of novel approaches to effectively target pancreatic cancer with radiation therapy. His team has successfully identified mechanisms responsible for locoregional recurrence after pancreatic cancer, namely characterization of extra-pancreatic neural tracts in the so-called “Baltimore Triangle.” He has translated this knowledge into effective strategies for radiation target volume delineation that have led to dramatic improvements in locoregional control. Moreover, he is exploring novel mechanism for dose-escalation, namely through the use of intra-operative radiation therapy, which remains an active of investigation and development. Additionally, he is exploring the combination of radiation therapy with novel agents such immunotherapies to enhance radiotherapeutic effect.

https://scholar.google.com/scholar?hl=en&q=amol+narang&btnG=&as_sdt=1%2C21&as_sdtp=

http://www.ncbi.nlm.nih.gov/pubmed/?term=amol+narang

• Hill C, Sehgal S, Fu W, et al: High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and 528 A. Narang locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy. Cancer Med 11(7):1659-1668, 2022
• Hill CS, Fu W, Seghal S, et al: Location, Location, Location: what should be targeted beyond gross disease for localized pancreatic ductal adenocarcinoma? Proposal of a standardized clinical target volume for pancreatic ductal adenocarcinoma of the head: the “Triangle Volume.” Pract Radiat Oncol 12(3):215-225, 2022
• Mao S, Lin TA, Sehgal S, et al: Utilization of the triangle volume in patients with localized PDAC undergoing pre-operative SBRT: report of early outcomes. Int J Radiat Oncol Biol Phys 117(2):S14, 2023 27.
• Reddy AV, Hill CS, Zheng L, et al: A safety study of intraoperative radiation therapy following stereotactic body radiation therapy and multi-agent chemotherapy in the treatment of localized pancreatic adenocarcinoma: study protocol of a phase I trial. Radiat Oncol 173, 2022(17)
• Sanford NN, Narang AK, Aguilera TA, et al: NRG oncology interna?tional consensus contouring atlas on target volumes and dosing strategies for dose-escalated pancreatic cancer radiation therapy. Int J Radiat Oncol Biol Phys 121(4):918-929, 2025
• Narang AK. Optimal Target Volume Delineation for Pancreatic Cancer: Triangulating What Should be Targeted. Semin Radiat Oncol. 2025 Oct;35(4):524-52.

• Frank L. Coulson Award for Clinical Excellence, Miller-Coulson Academy, 1/1/16
• Conquer Cancer Foundation Oncology Trainee Travel Award, American Society of Clinical Oncology Annual Meeting, 1/1/15
• Intern of the Year, Inova Fairfax Hospital, 1/1/12
• "Phase I trial investigating ABT-888, a novel PARP-inhibitor, as a radiosensitizer for patients with breast cancer", McCabe Pilot Award, 1/1/12

• Financial burden in Medicare patients with newly diagnosed cancer, Presentation, . American Society of Therapeutic Radiation Oncology Annual Meeting, San Antonio, TX, 10/1/15
• Predictors of high-grade histology in patients with progressive low-grade gliomas. Is histology needed to guide therapy?, Presentation, American Society of Therapeutic Radiation Oncology Annual Meeting, Atlanta, GA, 9/1/13
• Very-high-risk localized prostate cancer - outcomes following definitive radiation., Presentation, American Society of Therapeutic Radiation Oncology Annual Meeting, 9/1/14

• American Society for Radiation Oncology (ASTRO)
• American Society of Clinical Oncology (ASCO)
• American College of Radiation Oncology (ACRO)
• American Board of Radiology (ABR)